Please ensure Javascript is enabled for purposes of website accessibility

Why Celldex Therapeutics Stock Is Cratering Today

By George Budwell – Apr 16, 2018 at 8:50AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Celldex's highly anticipated breast cancer drug fails to hit the mark in a midstage trial.

What happened

Shares of Celldex Therapeutics (CLDX 1.85%), a small-cap cancer company, are down by over 43% in pre-market trading today on extremely heavy volume. What's going on?

Celldex's shares are cratering in response to the news that its once promising triple negative breast cancer (TNBC) drug candidate, glembatumumab vedotin (glemba), failed to meet its primary end point of improving progression-free survival, compared to patients receiving capecitabine in the midstage trial known as METRIC. Celldex has decided to also abandon glemba's other ongoing clinical studies in the wake of this disappointing outcome. 

Female cancer patient sitting on a chair.

Image Source: Getty Images.

So what

Glemba had the potential to transform Celldex into a commercial stage biotech by as early as next year. The company was widely expected to petition the Food and Drug Administration for an accelerated approval if METRIC was a success.

Unfortunately, glemba no longer is an obvious lead candidate as a stand-alone therapy after this clinical failure. The net result is that the biotech now appears to be years away from producing a drug capable of generating significant amounts of revenue.  

Now what

The silver lining is that Celldex did prepare itself to some degree for a negative outcome in METRIC by advancing its earlier stage assets into human trials late last year. In the waning weeks of 2017, for instance, Celldex initiated clinical trials for CDX-3379 in recurrent head and neck squamous cell cancer, and CDX-1140 in solid tumors. In total, the biotech has five other clinical candidates currently in trials that could help to soften the blow from this latest setback. 

That being said, Celldex is likely going to reassess its clinical program even further after glemba's failure. The company doesn't have the financial resources to advance all of these clinical candidates simultaneously. As such, it might be a good idea to shy away from this falling knife until the dust has settled.

George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends Celldex Therapeutics. The Motley Fool has a disclosure policy.

Stocks Mentioned

Celldex Therapeutics Stock Quote
Celldex Therapeutics
$37.34 (1.85%) $0.68

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.